Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures
| Autor: | Chahine, Lana M, Siderowf, Andrew, Barnes, Janel, Seedorff, Nicholas, Caspell-Garcia, Chelsea, Simuni, Tanya, Coffey, Christopher S, Galasko, Douglas, Mollenhauer, Brit, Arnedo, Vanessa, Daegele, Nichole, Frasier, Mark, Tanner, Caroline, Kieburtz, Karl, Marek, Kenneth, The Parkinson’s Progression Markers Initiative |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Dopamine Plasma Membrane Transport Proteins Parkinson's Disease Neurosciences Brain biomarkers Parkinson Disease The Parkinson’s Progression Markers Initiative Middle Aged Neurodegenerative Severity of Illness Index Brain Disorders disease progression Clinical Research Neurological Parkinson’s disease surrogate endpoint Humans Female sense organs Prospective Studies Biochemistry and Cell Biology Aged |
| Zdroj: | Journal of Parkinson's disease, vol 9, iss 4 |
| Popis: | BackgroundImproved prediction of Parkinson's disease (PD) progression is needed to support clinical decision-making and to accelerate research trials.ObjectivesTo examine whether baseline measures and their 1-year change predict longer-term progression in early PD.MethodsParkinson's Progression Markers Initiative study data were used. Participants had disease duration ≤2 years, abnormal dopamine transporter (DAT) imaging, and were untreated with PD medications. Baseline and 1-year change in clinical, cerebrospinal fluid (CSF), and imaging measures were evaluated as candidate predictors of longer-term (up to 5 years) change in Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) score and DAT specific binding ratios (SBR) using linear mixed-effects models.ResultsAmong 413 PD participants, median follow-up was 5 years. Change in MDS-UPDRS from year-2 to last follow-up was associated with disease duration (β= 0.351; 95% CI = 0.146, 0.555), male gender (β= 3.090; 95% CI = 0.310, 5.869), and baseline (β= -0.199; 95% CI = -0.315, -0.082) and 1-year change (β= 0.540; 95% CI = 0.423, 0.658) in MDS-UPDRS; predictors in the model accounted for 17.6% of the variance in outcome. Predictors of percent change in mean SBR from year-2 to last follow-up included baseline rapid eye movement sleep behavior disorder score (β= -0.6229; 95% CI = -1.2910, 0.0452), baseline (β= 7.232; 95% CI = 2.268, 12.195) and 1-year change (β= 45.918; 95% CI = 35.994,55.843) in mean striatum SBR, and 1-year change in autonomic symptom score (β= -0.325;95% CI = -0.695, 0.045); predictors in the model accounted for 44.1% of the variance.ConclusionsBaseline clinical, CSF, and imaging measures in early PD predicted change in MDS-UPDRS and dopamine-transporter binding, but the predictive value of the models was low. Adding the short-term change of possible predictors improved the predictive value, especially for modeling change in dopamine-transporter binding. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|